News

Jushi Announces Grand Reopening of Beyond Hello™ Palm Springs

Jushi Holdings Inc. Announces Grand Reopening of Palm Springs Dispensary Jushi Holdings Inc. to host the grand reopening of its…

2 years ago

Quipt Surpasses 200,000 Active Patients Adding Approximately $7 Million in Annualized Revenues, and Anticipated $1.4 Million of Adjusted EBITDA Post Integration

Acquisition of Hometown Medical, LLC Significantly Enhances Presence in MississippiCINCINNATI, July 11, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp.…

2 years ago

Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that…

2 years ago

Axogen, Inc. Appoints William Burke to Board of Directors

Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of DirectorsALACHUA, Fla. and TAMPA, Fla.,…

2 years ago

EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors

WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and…

2 years ago

MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

MW005 Shown to Be Safe and Well-ToleratedTarget Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept YAVNE, Israel, July 11, 2022 (GLOBE…

2 years ago

TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology

TScan screening technology used to identify the targets of expanded T cell clones in the tumors of patients with head…

2 years ago

Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder

Naloxone-Free Formulation of Tianeptine is an Extended-Release Tablet that Includes Inactive Ingredients and Compression Properties Designed to Confer Abuse Deterrence…

2 years ago

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:…

2 years ago

Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV

PRESS RELEASE Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV IMC-M113V, T cell receptor bispecific, targets an…

2 years ago